Roswell Park researchers identified a promising strategy to overcome resistance to KRAS-targeted cancer therapies.
News|Videos|November 10, 2025
Rezatapopt For Locally Advanced or Metastatic Solid Tumors With a TP53 Y220C Mutation: Initial Analysis of the Pivotal PYNNACLE Phase 2 Trial
Author(s)Alison Schram, MD
Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center, discusses initial results from the pivotal Phase 2 PYNNACLE trial evaluating rezatapopt, a first-in-class p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Advertisement
Advertisement
Related to this article
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
Advertisement
Advertisement
Trending on OncLive
1
Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma
2
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer
3
Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC
4
EU, Japanese Approval Is Sought for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated NSCLC
5